See more : Japan Logistics Fund, Inc. (8967.T) Income Statement Analysis – Financial Results
Complete financial analysis of MedMira Inc. (MMIRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedMira Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- J Frontier Co.,Ltd. (2934.T) Income Statement Analysis – Financial Results
- Kushim, Inc. (2345.T) Income Statement Analysis – Financial Results
- Nanjing Vazyme Biotech Co., Ltd. (688105.SS) Income Statement Analysis – Financial Results
- Zaklady Urzadzen Komputerowych ELZAB S.A. (ELZ.WA) Income Statement Analysis – Financial Results
- Evergreen Products Group Limited (1962.HK) Income Statement Analysis – Financial Results
MedMira Inc. (MMIRF)
About MedMira Inc.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 412.57K | 432.53K | 952.13K | 2.14M | 919.07K | 527.45K | 588.87K | 747.34K | 2.26M | 4.05M | 2.53M | 2.00M | 970.63K | 909.87K | 1.07M | 1.14M | 1.52M | 1.71M | 2.09M | 2.66M | 2.44M | 1.18M | 114.65K | 373.68K | 78.43K |
| Cost of Revenue | 186.08K | 132.15K | 648.10K | 422.73K | 346.79K | 104.09K | 127.76K | 269.05K | 1.24M | 2.87M | 1.75M | 1.37M | 376.40K | 493.91K | 338.15K | 580.24K | 986.30K | 906.33K | 950.08K | 1.57M | 1.15M | 749.84K | 448.08K | 342.24K | 28.33K |
| Gross Profit | 226.49K | 300.38K | 304.03K | 1.72M | 572.28K | 423.35K | 461.11K | 478.30K | 1.02M | 1.18M | 774.80K | 630.78K | 594.24K | 415.96K | 735.02K | 557.41K | 538.22K | 798.99K | 1.14M | 1.09M | 1.29M | 426.66K | -333.44K | 31.44K | 50.10K |
| Gross Profit Ratio | 54.90% | 69.45% | 31.93% | 80.29% | 62.27% | 80.26% | 78.30% | 64.00% | 45.16% | 29.13% | 30.65% | 31.52% | 61.22% | 45.72% | 68.49% | 49.00% | 35.30% | 46.85% | 54.57% | 40.83% | 52.70% | 36.27% | -290.84% | 8.41% | 63.88% |
| Research & Development | 476.89K | 470.68K | 191.14K | 359.32K | 199.27K | 317.35K | 522.94K | 292.30K | 2.52M | 604.14K | 294.43K | 133.30K | 199.02K | 275.27K | 332.36K | 317.30K | 333.60K | 329.25K | 653.62K | 471.73K | 502.58K | 819.35K | 1.20M | 1.70M | 761.22K |
| General & Administrative | 1.20M | 842.61K | 734.83K | 490.59K | 1.17M | 905.90K | 1.20M | 1.20M | 1.47M | 1.92M | 2.35M | 2.10M | 2.50M | 1.97M | 2.67M | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 661.91K |
| Selling & Marketing | 283.13K | 196.11K | 14.74K | 44.30K | 40.33K | 131.22K | 206.68K | 500.84K | 792.46K | 503.54K | 1.09M | 262.27K | 33.32K | 2.21K | 40.46K | 67.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 413.23K |
| SG&A | 1.48M | 1.04M | 749.58K | 534.89K | 1.21M | 1.04M | 1.41M | 1.70M | 2.27M | 2.42M | 3.44M | 2.36M | 2.54M | 1.97M | 2.71M | 2.73M | 3.36M | 3.82M | 5.79M | 4.98M | 3.94M | 3.57M | 3.26M | 4.67M | 1.08M |
| Other Expenses | 843.11K | 735.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.55K | 313.90K | -270.53K | -1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.80M | 2.24M | 1.57M | 1.72M | 1.87M | 1.72M | 2.30M | 2.61M | 5.50M | 3.65M | 4.34M | 2.80M | 2.75M | 2.27M | 3.07M | 3.08M | 3.86M | 4.37M | 6.62M | 5.53M | 4.78M | 4.74M | 4.78M | 6.73M | 3.36M |
| Cost & Expenses | 2.99M | 2.38M | 2.22M | 2.14M | 2.22M | 1.82M | 2.43M | 2.88M | 6.74M | 6.52M | 6.10M | 4.17M | 3.13M | 2.77M | 3.41M | 3.66M | 4.85M | 5.28M | 7.57M | 7.11M | 5.93M | 5.49M | 5.23M | 7.07M | 3.39M |
| Interest Income | -14.00K | 885.52K | 552.04K | 653.30K | 725.63K | 810.42K | 28.00K | 449.89K | 260.00K | 0.00 | 479.82K | 734.60K | -66.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 882.41K | 0.00 | 552.04K | 653.30K | 725.63K | 810.42K | 697.17K | 0.00 | 939.56K | 769.19K | 760.71K | 0.00 | 3.79M | 3.60M | 2.40M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 309.55K | 212.90K | 212.30K | 207.80K | 193.17K | 18.86K | 66.77K | 98.79K | 99.79K | 94.08K | 479.82K | -245.46K | 19.33K | 30.11K | 33.55K | 42.08K | 179.18K | 217.70K | 209.40K | 112.60K | 333.84K | 345.69K | 323.96K | 368.26K | 321.51K |
| EBITDA | -2.13M | -1.58M | -1.07M | 185.30K | -1.13M | -1.28M | -1.75M | -2.11M | -4.38M | -2.65M | -2.99M | -2.41M | -2.14M | -1.30M | -2.30M | -2.48M | -3.15M | -3.35M | -5.27M | -4.33M | -3.16M | -3.96M | -4.79M | -6.33M | -2.99M |
| EBITDA Ratio | -517.33% | -364.66% | -112.09% | 8.64% | -122.58% | -242.14% | -296.42% | -282.65% | -182.52% | -58.67% | -122.18% | -120.45% | -220.59% | -142.38% | -214.67% | -218.40% | -211.55% | -196.61% | -251.94% | -162.92% | -129.59% | -337.02% | -4,176.94% | -1,694.50% | -3,806.44% |
| Operating Income | -2.57M | -1.94M | -1.45M | -184.23K | -1.30M | -1.30M | -1.84M | -2.13M | -4.48M | -2.47M | -3.57M | -2.17M | -2.16M | -1.86M | -2.34M | -2.53M | -3.25M | -3.57M | -5.48M | -4.45M | -3.49M | -4.31M | -5.11M | -6.70M | -3.31M |
| Operating Income Ratio | -623.65% | -449.52% | -152.63% | -8.59% | -141.46% | -245.72% | -312.51% | -285.43% | -198.46% | -60.99% | -141.15% | -108.19% | -222.58% | -204.11% | -217.79% | -222.10% | -213.09% | -209.37% | -261.95% | -167.15% | -143.28% | -366.40% | -4,459.52% | -1,793.05% | -4,216.38% |
| Total Other Income/Expenses | -753.33K | -731.34K | -378.35K | -491.57K | -745.23K | -810.42K | -669.17K | -527.90K | -679.54K | -488.09K | -266.72K | 1.76M | 5.74M | -3.07M | 313.90K | -270.53K | -963.43K | 18.56K | 592.00 | 1.21K | 40.69K | 147.93K | 209.91K | 116.63K | 0.00 |
| Income Before Tax | -3.33M | -2.68M | -1.83M | -675.80K | -2.05M | -2.11M | -2.51M | -2.66M | -5.16M | -3.23M | -3.84M | -402.30K | 3.37M | -4.93M | -2.02M | -2.80M | -4.21M | -3.55M | -5.48M | -4.45M | -3.45M | -4.16M | -4.90M | -6.58M | 0.00 |
| Income Before Tax Ratio | -806.25% | -618.61% | -192.37% | -31.51% | -222.55% | -399.37% | -426.15% | -356.07% | -228.57% | -79.70% | -151.70% | -20.10% | 347.43% | -541.75% | -188.54% | -245.87% | -276.29% | -208.29% | -261.93% | -167.11% | -141.61% | -353.83% | -4,276.42% | -1,761.84% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 173.68K | 161.73K | -19.60K | -153.00K | 28.00K | -78.01K | 939.56K | 769.19K | 280.89K | 980.06K | 3.79M | -37.00K | 2.40M | 2.47M | 2.65M | 2.74M | 1.81M | 1.66M | 538.91K | 453.19K | 755.39K | 612.74K | -409.66K |
| Net Income | -3.33M | -2.68M | -1.83M | -675.80K | -2.05M | -2.11M | -2.51M | -2.66M | -5.16M | -3.23M | -3.84M | -402.30K | 3.37M | -4.89M | -4.42M | -5.26M | -7.02M | -6.29M | -7.29M | -6.11M | -3.99M | -4.62M | -5.66M | -7.20M | -2.90M |
| Net Income Ratio | -806.25% | -618.61% | -192.37% | -31.51% | -222.55% | -399.37% | -426.15% | -356.07% | -228.57% | -79.70% | -151.70% | -20.10% | 347.43% | -537.68% | -411.74% | -462.64% | -460.34% | -368.70% | -348.46% | -229.51% | -163.71% | -392.35% | -4,935.31% | -1,925.81% | -3,694.04% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.01 | -0.02 | -0.02 | -0.05 | -0.09 | -0.10 | -0.15 | -0.14 | -0.10 | -0.18 | -0.27 | -0.35 | -0.14 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.01 | -0.02 | -0.02 | -0.05 | -0.09 | -0.10 | -0.15 | -0.14 | -0.10 | -0.18 | -0.27 | -0.35 | -0.14 |
| Weighted Avg Shares Out | 697.67M | 668.91M | 680.65M | 658.33M | 658.36M | 658.36M | 627.52M | 658.36M | 644.80M | 558.36M | 514.36M | 392.26M | 278.99M | 216.59M | 188.20M | 116.45M | 81.88M | 60.99M | 48.59M | 43.62M | 39.93M | 25.26M | 20.96M | 20.48M | 20.48M |
| Weighted Avg Shares Out (Dil) | 697.67M | 697.45M | 680.65M | 658.33M | 658.36M | 658.36M | 658.36M | 658.36M | 658.36M | 558.36M | 514.36M | 392.26M | 411.70M | 216.59M | 188.20M | 116.45M | 81.88M | 60.99M | 48.59M | 43.62M | 40.55M | 25.26M | 20.96M | 20.48M | 20.48M |
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023, the Company received the 510(k) (FDA) approval for...
MedMira Announces the appointment of Vice President of Commercial Operations
MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vice President of Commercial Operations, effective immediately. Ms. Crenshaw's addition strengthens...
MedMira Reports Third Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focused on the launch of MedMira's latest US...
MedMira Announces the Hire of Vice President of Business Development
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development.
MedMira Reports Second Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira received the US FDA 510(k) clearance for the...
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent...
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada.
Corporate Update on Clinical Evaluation of MedMira's Products
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required submission and has been working towards extending...
MedMira Reports First Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2023. Corporate update During Q1 FY2024, MedMira continued its focus on its regulatory and clinical...
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. This...
Source: https://incomestatements.info
Category: Stock Reports